TRIP13 is a potential prognostic marker and therapeutic target for endometrial cancer

Uterine corpus endometrial carcinoma (UCEC) is a prevalent malignancy within the female reproductive system, exhibiting a rising global incidence. The thyroid hormone receptor interacting protein 13 (TRIP13) has been implicated in various tumor etiologies and progressions, but its role in UCEC remains poorly characterized. This study aimed to delineate TRIP13's expression profile in UCEC by analyzing transcriptome data across multiple databases. Genomic alterations and epigenetic modifications of the TRIP13 gene were investigated using the cBioPortal tool. The prognostic value of TRIP13 was evaluated through Kaplan-Meier survival analysis and Cox regression modeling. Furthermore, the study examined TRIP13's impact on immunotherapy responsiveness and chemotherapy sensitivity via immunological and pharmacological analyses. The expression of TRIP13 in endometrial cancer cell lines was validated using Quantitative Real-time Polymerase Chain Reaction (qPCR). Our findings reveal that TRIP13 expression in UCEC tumor samples is significantly higher than in normal tissues and increases with tumor grade and stage progression. High TRIP13 expression is significantly associated with poor prognosis in UCEC patients, establishing it as an independent prognostic biomarker. TRIP13 shows a positive correlation with immunosuppressive cell infiltration and a negative correlation with immune-activating cell infiltration, suggesting a potential role in tumor immune evasion. Further analysis identified TRIP13 as a potential biomarker for predicting immunotherapy response. Moreover, TRIP13 expression was significantly associated with the sensitivity to certain chemotherapeutic agents, indicatin